The US FDA Has Approved The Listing Of Six Nicotine Pouch Products.

After approving 20 ZYN nicotine pouch products for market on January 16, 2025, the FDA recently approved another batch of nicotine pouch products. On December 19, the FDA announced that it had approved the marketing authorization of 6 nicotine pouch products through the Pre-Market Tobacco Product Application (PMTA) process.
The approved products are manufactured by Helix Innovations LLC and sold under the brand name on! PLUS. The approved products cover various flavors and nicotine concentrations, including: on! PLUS nicotine pouch mint flavor, 6 mg on! PLUS nicotine pouch mint flavor, 9 mg on! PLUS nicotine pouch tobacco flavor, 6 mg on! PLUS nicotine pouch tobacco flavor, 9 mg on! PLUS nicotine pouch wintergreen flavor, 6 mg on! PLUS nicotine pouch wintergreen flavor, 9 mg.
The FDA stated that, after scientific review, it determined that these nicotine pouch products comply with the legal standards for selling new tobacco products in the United States as stipulated in the 2009 "Family Smoking Prevention and Tobacco Control Act". These standards require the FDA to consider the risks and benefits to the entire American population - including the benefits to adults who have switched from using tobacco products to potentially lower-risk products, which are sufficient to outweigh the risks of the product, and also the benefits to current non-tobacco-using teenagers and adults.
The key findings in the FDA's assessment include:
Compared with other oral or smokeless tobacco products, most harmful and potentially harmful components (HPHCs) in the new products have lower levels, and many components have extremely low concentrations that are difficult to quantify.
No measurable levels of several carcinogenic HPHCs were detected, including components known to significantly increase the risk of oral cancer for adult non-smokers.
It may provide sufficient benefits for adult smokers and/or other smokeless tobacco users to offset the product risks (including risks to teenagers).
The acting director of the FDA's Tobacco Products Center, Dr. Brett Copello (J.D.), said: "Today's marketing approval confirms that strict and efficient scientific research standards are not mutually exclusive. Thanks to the FDA's nicotine pilot program, adult smokers who wish to switch to lower-risk alternative tobacco products now have more choices."